Oct. 11, 2006 Parkinson disease patients who develop impulse control disorders as a result of treatment are more likely to be depressed, irritable, and have appetite changes, according to a study published in the October 10, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology. These findings could allow early identification of patients at risk for developing this distressing complication of treatment.
Compulsive gambling, hypersexuality, and excessive shopping have been linked to treatment with dopamine agonists in small numbers of patients. It is unknown exactly how many patients experience such an impulse control disorder, although it is believed to be less than 10 percent of those receiving these drugs.
To identify risk factors for development of impulse control disorder, the authors studied 100 Parkinson disease patients, including 66 men and 34 women, who were receiving the full range of standard anti-Parkinson medications, including levodopa, dopamine agonists, and other drugs. They administered a standard battery of psychiatric tests to identify the presence of depression, anxiety, delusions, and other psychiatric conditions, as well as impulse control disorder.
They found that nine of the 100 patients had an impulse control disorder, including four with pathological gambling, two with hypersexuality, one with excessive shopping, and two with both hypersexuality and excessive shopping. All nine were receiving a dopamine agonist, in addition to other medications.
Compared to patients without an impulse control disorder, patients with one were more than twice as likely to have depressive symptoms, were more than three times as likely to have appetite changes, and were more than six times as likely to have symptoms of irritability and disinhibition.
"These results highlight the potential usefulness of depression and appetite changes as 'sentinel symptoms' associated with an impulse control disorder," according to lead study author Laura Marsh, MD, with Johns Hopkins University School of Medicine in Baltimore, Maryland, and a member of the American Academy of Neurology. "Since only a small fraction of patients receiving dopamine agonists develop this disorder, these findings may help identify those most at risk. Strategies for treatment may include changing medications or avoiding situations that may lead to the impulsive behavior."
The study was supported by grants from the National Institutes of Health.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.